BENEFITS AND RISKS OF USING ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN NON-SMALL CELL LUNG CANCER (NSCLC) AND SMALL CELL LUNG CANCER (SCLC) PATIENTS: RESULTS FROM STUDY-LEVEL AND PATIENT-LEVEL META-ANALYSES OF CONTROLLED ESA TRIALS IN LUNG CANCER
Publication
, Conference
Vansteenkiste, J; Glaspy, J; Henry, D; Ludwig, H; Pirker, R; Tomita, D; Collins, H; Crawford, J
Published in: JOURNAL OF THORACIC ONCOLOGY
June 1, 2011
Duke Scholars
Published In
JOURNAL OF THORACIC ONCOLOGY
EISSN
1556-1380
ISSN
1556-0864
Publication Date
June 1, 2011
Volume
6
Issue
6
Start / End Page
S645 / S646
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Vansteenkiste, J., Glaspy, J., Henry, D., Ludwig, H., Pirker, R., Tomita, D., … Crawford, J. (2011). BENEFITS AND RISKS OF USING ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN NON-SMALL CELL LUNG CANCER (NSCLC) AND SMALL CELL LUNG CANCER (SCLC) PATIENTS: RESULTS FROM STUDY-LEVEL AND PATIENT-LEVEL META-ANALYSES OF CONTROLLED ESA TRIALS IN LUNG CANCER. In JOURNAL OF THORACIC ONCOLOGY (Vol. 6, pp. S645–S646). LIPPINCOTT WILLIAMS & WILKINS.
Vansteenkiste, Johan, John Glaspy, David Henry, Heinz Ludwig, Robert Pirker, Dianne Tomita, Helen Collins, and Jeffrey Crawford. “BENEFITS AND RISKS OF USING ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN NON-SMALL CELL LUNG CANCER (NSCLC) AND SMALL CELL LUNG CANCER (SCLC) PATIENTS: RESULTS FROM STUDY-LEVEL AND PATIENT-LEVEL META-ANALYSES OF CONTROLLED ESA TRIALS IN LUNG CANCER.” In JOURNAL OF THORACIC ONCOLOGY, 6:S645–46. LIPPINCOTT WILLIAMS & WILKINS, 2011.
Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, et al. BENEFITS AND RISKS OF USING ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN NON-SMALL CELL LUNG CANCER (NSCLC) AND SMALL CELL LUNG CANCER (SCLC) PATIENTS: RESULTS FROM STUDY-LEVEL AND PATIENT-LEVEL META-ANALYSES OF CONTROLLED ESA TRIALS IN LUNG CANCER. In: JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS; 2011. p. S645–6.
Vansteenkiste, Johan, et al. “BENEFITS AND RISKS OF USING ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN NON-SMALL CELL LUNG CANCER (NSCLC) AND SMALL CELL LUNG CANCER (SCLC) PATIENTS: RESULTS FROM STUDY-LEVEL AND PATIENT-LEVEL META-ANALYSES OF CONTROLLED ESA TRIALS IN LUNG CANCER.” JOURNAL OF THORACIC ONCOLOGY, vol. 6, no. 6, LIPPINCOTT WILLIAMS & WILKINS, 2011, pp. S645–46.
Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J. BENEFITS AND RISKS OF USING ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN NON-SMALL CELL LUNG CANCER (NSCLC) AND SMALL CELL LUNG CANCER (SCLC) PATIENTS: RESULTS FROM STUDY-LEVEL AND PATIENT-LEVEL META-ANALYSES OF CONTROLLED ESA TRIALS IN LUNG CANCER. JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS; 2011. p. S645–S646.
Published In
JOURNAL OF THORACIC ONCOLOGY
EISSN
1556-1380
ISSN
1556-0864
Publication Date
June 1, 2011
Volume
6
Issue
6
Start / End Page
S645 / S646
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology